US 12,391,916 B2
Veto cells generated from memory T cells
Yair Reisner, Houston, TX (US); Noga Or-Geva, Rehovot (IL); Rotem Gidron Budovsky, Rehovot (IL); Esther Bachar-Lustig, Rehovot (IL); Assaf Lask, Rehovot (IL); and Sivan Kagan, Rehovot (IL)
Assigned to Yeda Research and Development Co. Ltd.
Filed by Yeda Research and Development Co. Ltd., Rehovot (IL)
Filed on Aug. 10, 2023, as Appl. No. 18/232,437.
Application 18/232,437 is a continuation of application No. 17/211,863, filed on Mar. 25, 2021, granted, now 11,773,372.
Application 17/211,863 is a continuation of application No. 16/313,486, granted, now 10,961,504, issued on Mar. 30, 2021, previously published as PCT/IL2017/050716, filed on Jun. 27, 2017.
Claims priority of provisional application 62/354,950, filed on Jun. 27, 2016.
Prior Publication US 2023/0383254 A1, Nov. 30, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/00 (2006.01); A61K 35/12 (2015.01); A61K 35/17 (2025.01); A61K 39/00 (2006.01); A61K 40/11 (2025.01); A61K 40/32 (2025.01); A61K 40/42 (2025.01); A61K 40/46 (2025.01); C12N 5/0783 (2010.01)
CPC C12N 5/0087 (2013.01) [A61K 39/001 (2013.01); A61K 40/11 (2025.01); A61K 40/32 (2025.01); A61K 40/42 (2025.01); A61K 40/46 (2025.01); C12N 5/0637 (2013.01); A61K 2035/122 (2013.01); A61K 35/17 (2013.01); C12N 2501/2307 (2013.01); C12N 2501/2315 (2013.01); C12N 2501/2321 (2013.01); C12N 2502/1121 (2013.01)] 27 Claims
 
1. A method of treating a disease in a subject in need thereof, the method comprising:
(i) generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, said cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation by:
(a) providing a population of T cells comprising at least 50% memory T cells;
(b) contacting said population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and
(c) culturing said cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising said Tcm phenotype; and
(ii) administering to the subject a therapeutically effective amount of the generated isolated population of non-GvHD inducing cells,
thereby treating the disease in the subject.